NHG-Standaard
M113
1.1
maart 2024
september 2024
W/X/Y. Zwangerschap / anticonceptie / geslachtsorganen man en vrouw
Richtlijnen diagnostiek
Naar Volledige tekst ›Anamnese
Naar Volledige tekst ›Counseling vroegdiagnostiek
Naar Volledige tekst ›Lichamelijk onderzoek
Naar Volledige tekst ›Aanvullend onderzoek
Naar Volledige tekst ›Evaluatie
Naar Volledige tekst ›Richtlijnen beleid
Naar Volledige tekst ›Achtergronden
Naar Samenvatting ›Begrippen
Naar Samenvatting ›Prostaatspecifiek antigeen
Naar Samenvatting ›Vroegdiagnostiek
Naar Samenvatting ›Prostaatkanker
Naar Samenvatting ›Familiaire prostaatkanker
Naar Samenvatting ›Erfelijke prostaatkanker
Naar Samenvatting ›Actief volgen (active surveillance)
Naar Samenvatting ›Waakzaam afwachten (watchful waiting)
Naar Samenvatting ›Epidemiologie
Naar Samenvatting ›Mate van uitbreiding
Naar Samenvatting ›Etiologie en prognose
Naar Samenvatting ›Familiaire prostaatkanker
Naar Samenvatting ›Erfelijkheid
Naar Samenvatting ›Behandelingen, complicaties en prognose
Naar Samenvatting ›Pathofysiologie en symptomatologie
Naar Samenvatting ›Vroegdiagnostiek
Naar Samenvatting ›Effecten van systematische screening
Naar Samenvatting ›Levensverwachting en vitaliteit
Naar Samenvatting ›Afweging wel of geen PSA-bepaling
Naar Samenvatting ›MRI van de prostaat
Naar Samenvatting ›Richtlijnen diagnostiek
Naar Samenvatting ›Anamnese
Naar Samenvatting ›Counseling over vroegdiagnostiek
Naar Samenvatting ›Bespreking
Naar Samenvatting ›Schriftelijke informatie
Naar Samenvatting ›Keuze
Naar Samenvatting ›Lichamelijk onderzoek
Naar Samenvatting ›Aanvullend onderzoek
Naar Samenvatting ›Indicaties voor PSA-meting
Naar Samenvatting ›Indicaties voor periodieke PSA-meting
Naar Samenvatting ›Situaties waarin PSA-meting niet wordt aanbevolen
Naar Samenvatting ›Uitvoering van de PSA-meting
Naar Samenvatting ›Evaluatie
Naar Samenvatting ›Richtlijnen beleid
Naar Samenvatting ›Voorlichting en advies
Naar Samenvatting ›Afwijkend rectaal toucher
Naar Samenvatting ›Lage PSA-waarde (< 1 ng/ml)
Naar Samenvatting ›Normale PSA-waarde (> 1 ng/ml maar < 3 ng/ml)
Naar Samenvatting ›Aanwijzingen van (bot-) metastasen
Naar Samenvatting ›Hogere PSA-waarden (≥ 3,0 ng/ml)
Naar Samenvatting ›Consultatie en verwijzing
Naar Samenvatting ›Aandachtspunten bij verwijzing
Naar Samenvatting ›Follow-up van (behandelde) prostaatkanker
Naar Samenvatting ›Referenties
- Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. Jama 1998;279:1542-7.
- Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 1997;79:104-9.
- Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009;27:398-403.
- Gezondheidsraad. Screening: tussen hoop en hype (2008).
- Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016;40:244-52.
- Kiemeney LA, Broeders MJ, Pelger M, Kil PJ, Schröder FH, Witjes JA, Vasen HF. Screening for prostate cancer in dutch hereditary prostate cancer families. Int J Cancer 2008;122:871-6.
- Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, et al. Prostate specific antigen working group guidelines on prostate specific antigen doubling time. J Urol 2008;179:2181-5; discussion 5-6.
- Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 2004;171:2122-7.
- Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 2003;97:1894-903.
- Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003;91:789-94.
- Johansson E, Bill-Axelson A, Holmberg L, Onelöv E, Johansson JE, Steineck G. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol 2009;55:422-30.
- Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016;375:1425-37.
- Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762-71.
- Fransson P. Fatigue in prostate cancer patients treated with external beam radiotherapy: a prospective 5-year long-term patient-reported evaluation. J Cancer Res Ther 2010;6:516-20.
- Wilt TJ, N'Dow J. Benign prostatic hyperplasia. Part 1-diagnosis. Bmj 2008;336:146-9.
- Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2023;388:1547-58.
- James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163-77.
- Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737-46.
- Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352-60.
- Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, Dahm P. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. Bmj 2010;341:c4543.
- Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. Bmj 2018;362:k3519.
- Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized european study. N Engl J Med 2009;360:1320-8.
- Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
- Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027-35.
- Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125-32.
- Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: The CAP randomized clinical trial. Jama 2018;319:883-95.
- Labrie F, Candas B, Cusan L, Gomez JL, Bélanger A, Brousseau G, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 quebec prospective randomized controlled trial. Prostate 2004;59:311-8.
- Lundgren PO, Kjellman A, Norming U, Gustafsson O. Long-term outcome of a single intervention population based prostate cancer screening study. J Urol 2018;200:82-8.
- Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol 2015;68:354-60.
- Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, et al. A 16-yr follow-up of the european randomized study of screening for prostate cancer. Eur Urol 2019;76:43-51.
- Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol 2012a;61:577-83.
- Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012;367:595-605.
- Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlén BJ, Holmberg L. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790-6.
- Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, et al. Complications after systematic, random, and image-guided prostate biopsy. Eur Urol 2017;71:353-65.
- Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur Urol 2013;64:876-92.
- Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 2001;166:856-60.
- Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol 2015;68:438-50.
- Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. Jama 2015;313:390-7.
- Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018;378:1767-77.
- Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG. Prostate MRI, with or without mri-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev 2019;4:Cd012663.
- Robinson D, Abdulkareem R, Nasrollah D, Ljung A, Hintze P, Wallby S, et al. Frequency of biopsy and tumor grade before versus after introduction of prostate magnetic resonance imaging. JAMA Netw Open 2023;6:e2330233.
- Hao S, Discacciati A, Eklund M, Heintz E, Östensson E, Elfström KM, et al. Cost-effectiveness of prostate cancer screening using magnetic resonance imaging or standard biopsy based on the STHLM3-MRI study. JAMA Oncol 2022;9:88-94.
- Blanker MH GF, Bosch JL, Thomas S, Prins A, Bohnen AM. Prevalentie van prostaatkanker gelijk bij mannen van 50 jaar of ouder met en zonder mictieklachten. Ned Tijdschr Geneesk 2003:973-8.
- Collin SM, Metcalfe C, Donovan J, Lane JA, Davis M, Neal D, et al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int 2008;102:1400-6.
- Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI. Lower urinary tract symptoms and risk of prostate cancer: the HUNT 2 Cohort, Norway. Int J Cancer 2008;123:1924-8.
- Merriel SWD, Funston G, Hamilton W. Prostate cancer in primary care. Adv Ther 2018;35:1285-94.
- Watson E, Hewitson P, Brett J, Bukach C, Evans R, Edwards A, et al. Informed decision making and prostate specific antigen (psa) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested. Patient Educ Couns 2006;63:367-79.
- Evans R, Joseph-Williams N, Edwards A, Newcombe RG, Wright P, Kinnersley P, et al. Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial. J Med Internet Res 2010;12:e27.
- Riikonen JM, Guyatt GH, Kilpeläinen TP, Craigie S, Agarwal A, Agoritsas T, et al. Decision aids for prostate cancer screening choice: a systematic review and meta-analysis. JAMA Intern Med 2019;179:1072-82.
- Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-90.
- Young SM, Bansal P, Vella ET, Finelli A, Levitt C, Loblaw A. Systematic review of clinical features of suspected prostate cancer in primary care. Can Fam Physician 2015;61:e26-35.
- Naji L, Randhawa H, Sohani Z, Dennis B, Lautenbach D, Kavanagh O, et al. Digital rectal examination for prostate cancer screening in primary care: a systematic review and meta-analysis. Ann Fam Med 2018;16:149-54.
- Gosselaar C, Roobol MJ, Roemeling S, Schröder FH. The role of the digital rectal examination in subsequent screening visits in the european randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol 2008;54:581-8.
- Walsh AL, Considine SW, Thomas AZ, Lynch TH, Manecksha RP. Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study. Br J Gen Pract 2014;64:e783-7.
- Borden LS, Jr., Wright JL, Kim J, Latchamsetty K, Porter CR. An abnormal digital rectal examination is an independent predictor of gleason > or =7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men. BJU Int 2007;99:559-63.
- Hoogendam A, Buntinx F, de Vet HC. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. Fam Pract 1999;16:621-6.
- Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, Catalona WJ. Characteristics of prostate cancer detected by digital rectal examination only. Urology 2007;70:1117-20.
- Anonymous. Effect of digital rectal examination on serum prostate-specific antigen in a primary care setting. The Internal Medicine Clinic Research Consortium. Arch Intern Med 1995;155:389-92.
- Chybowski FM, Bergstralh EJ, Oesterling JE. The effect of digital rectal examination on the serum prostate specific antigen concentration: results of a randomized study. J Urol 1992;148:83-6.
- Crawford ED, Schutz MJ, Clejan S, Drago J, Resnick MI, Chodak GW, et al. The effect of digital rectal examination on prostate-specific antigen levels. Jama 1992;267:2227-8.
- Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol 2006;176:868-74.
- Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Björk T, Gerdtsson A, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. Bmj 2013;346:f2023.
- Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
- Vickers AJ, Cronin AM, Björk T, Manjer J, Nilsson PM, Dahlin A, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. Bmj 2010;341:c4521.
- Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, Vickers A. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. Bmj 2014;348:g2296.
- Roobol MJ, Schröder FH, Hugosson J, Jones JS, Kattan MW, Klein EA, et al. Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol 2012b;30:149-55.
- Kranse R, Roobol M, Schröder FH. A graphical device to represent the outcomes of a logistic regression analysis. Prostate 2008;68:1674-80.
- Dong F, Kattan MW, Steyerberg EW, Jones JS, Stephenson AJ, Schröder FH, Klein EA. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol 2008;180:150-4; discussion 4.
- Trottier G, Roobol MJ, Lawrentschuk N, Boström PJ, Fernandes KA, Finelli A, et al. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for prostate cancer in a contemporary Canadian cohort. BJU Int 2011;108:E237-44.
- Cavadas V, Osório L, Sabell F, Teves F, Branco F, Silva-Ramos M. Prostate cancer prevention trial and european randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur Urol 2010;58:551-8.
- van Vugt HA, Roobol MJ, Kranse R, Määttänen L, Finne P, Hugosson J, et al. Prediction of prostate cancer in unscreened men: external validation of a risk calculator. Eur J Cancer 2011;47:903-9.